Gastroparesis Drugs Market Report 2026

Gastroparesis Drugs Market Overview

• Gastroparesis Drugs market size has reached to $5.7 billion in 2025 • Expected to grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Increasing Prevalence Of Diabetes Fuels Growth In The Gastroparesis Drugs Market • Market Trend: Advances In Novel Therapies Aim To Improve Stomach Motility And Relieve Digestive Symptoms • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gastroparesis Drugs Market?

Gastroparesis drugs are medications used to manage and treat gastroparesis, a condition where the stomach's ability to empty its contents is delayed, causing symptoms such as nausea, vomiting, and abdominal pain. These drugs typically include prokinetics to stimulate stomach motility, antiemetics to control nausea and vomiting, and medications to manage pain and other symptoms associated with the condition. The main drug types of gastroparesis drugs are over-the-counter (OTC) drugs and prescription drugs. Over-the-counter (OTC) drugs are medications that can be purchased without a prescription from a healthcare professional. These drugs are used to treat various disease types, such as diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, and others, and are consumed through various routes of administration, mainly oral, injectable, and others. Several drug types include prokinetic agents, antiemetic drugs, proton pump inhibitors, others, which are sold through hospitals, pharmacies, clinics, and e-commerce distribution channels.

What Is The Gastroparesis Drugs Market Growth Forecast?

The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising global diabetes prevalence, growing awareness of gastroparesis as a chronic condition, increasing demand for effective long-term symptom control, expansion of access to specialty gastrointestinal care, ongoing need for improved motility-enhancing therapies. Major trends in the forecast period include growing reliance on prokinetic agents for symptom management, increasing use of combination drug therapy for gastroparesis, rising demand for prescription-based gastroparesis treatments, expansion of symptom-focused treatment approaches, greater use of oral drug formulations for long-term management.

Global Gastroparesis Drugs Market Segmentation

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs 2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes 3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types 4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration 5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce Subsegments: 1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements 2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

What Is The Driver Of The Gastroparesis Drugs Market?

The increasing prevalence of diabetes is expected to propel the growth of the gastroparesis drugs market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels resulting from insufficient insulin production or impaired insulin utilization. The prevalence of diabetes is rising due to sedentary lifestyles, unhealthy dietary behaviors, genetic predisposition, urbanization, aging populations, and growing obesity rates. The gastroparesis drugs market supports diabetes care by providing medications that relieve symptoms such as nausea, vomiting, and delayed gastric emptying common gastrointestinal complications associated with diabetic gastroparesis. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while type 2 diabetes patients saw a 21% increase, and the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit. Therefore, the increasing prevalence of diabetes is driving the growth of the gastroparesis drugs industry.

Key Players In The Global Gastroparesis Drugs Market

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Global Gastroparesis Drugs Market Trends and Insights

Major companies operating in the gastroparesis drugs market are focusing on developing innovative solutions such as novel prokinetic therapies to improve gastric motility and reduce symptoms. Novel prokinetic therapies are new medications designed to stimulate and enhance the normal movement of the stomach and intestines to help food pass more effectively. For instance, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. This approval is for tradipitant, an investigational oral neurokinin-1 receptor antagonist, to treat gastroparesis, a serious digestive disorder with unmet medical needs. This acceptance marks a key regulatory milestone for Vanda as it continues to pursue marketing authorization for tradipitant in gastroparesis patients.

What Are Latest Mergers And Acquisitions In The Gastroparesis Drugs Market?

In May 2025, Renexxion Ireland Ltd., an Ireland-based biopharmaceutical company, partnered with Dr. Falk Pharma GmbH to advance the global development of naronapride for the treatment of gastroparesis. This partnership aims to complete the global Phase 2b MOVE‑IT study and accelerate the development of Naronapride as a potential best-in-class therapy for gastroparesis. Dr. Falk Pharma GmbH is a Germany-based company that specializes in digestive and metabolic medicine.

Regional Insights

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gastroparesis Drugs Market?

The gastroparesis drugs market consists of sales of metoclopramide, ondansetron, amitriptyline, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gastroparesis Drugs Market Report 2026?

The gastroparesis drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.